- Home
- DOMH vs IMMX Comparison
DOMH vs IMMX Comparison
Compare DOMH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- IMMX
- Stock Information
- Founded
- DOMH 1967
- IMMX 2014
- Country
- DOMH United States
- IMMX United States
- Employees
- DOMH N/A
- IMMX N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- DOMH Health Care
- IMMX Health Care
- Exchange
- DOMH Nasdaq
- IMMX Nasdaq
- Market Cap
- DOMH 71.2M
- IMMX 61.1M
- IPO Year
- DOMH N/A
- IMMX 2021
- Fundamental
- Price
- DOMH $5.70
- IMMX $2.35
- Analyst Decision
- DOMH
- IMMX Strong Buy
- Analyst Count
- DOMH 0
- IMMX 1
- Target Price
- DOMH N/A
- IMMX $7.00
- AVG Volume (30 Days)
- DOMH 322.3K
- IMMX 540.4K
- Earning Date
- DOMH 08-07-2025
- IMMX 08-11-2025
- Dividend Yield
- DOMH 5.63%
- IMMX N/A
- EPS Growth
- DOMH N/A
- IMMX N/A
- EPS
- DOMH N/A
- IMMX N/A
- Revenue
- DOMH $24,891,000.00
- IMMX N/A
- Revenue This Year
- DOMH N/A
- IMMX N/A
- Revenue Next Year
- DOMH N/A
- IMMX N/A
- P/E Ratio
- DOMH N/A
- IMMX N/A
- Revenue Growth
- DOMH 630.80
- IMMX N/A
- 52 Week Low
- DOMH $0.83
- IMMX $1.26
- 52 Week High
- DOMH $13.58
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- DOMH 63.00
- IMMX 54.87
- Support Level
- DOMH $4.90
- IMMX $2.20
- Resistance Level
- DOMH $5.59
- IMMX $2.46
- Average True Range (ATR)
- DOMH 0.50
- IMMX 0.27
- MACD
- DOMH 0.11
- IMMX -0.01
- Stochastic Oscillator
- DOMH 82.16
- IMMX 44.39
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.